Oppenheimer’s Favorite Stocks For Next 12 Months: Top 32 Stock Picks

Page 26 of 32

7. Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP)

Share Price Upside: 38%

Number of Hedge Fund Investors In Q2 2024: 30

Average Analyst Share Price Target: $82.67

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) is a small biotechnology company developing treatments for cancer and obesity. The firm’s two lead drug candidates are its weight loss drug called CRB-913 and its cervical cancer treatment dubbed as CRB-701. Among these, while CRB-913 is leading development as it is currently in a phase one trial in China, Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP)’s CRB-701 has generated more hype in investors. This is because the drug is a CB1 receptor inverse agonist, which regulates GLP-1 levels in the human body. A similar CB1 treatment is being developed by pharma giant Novo Nordisk, after its $1 billion acquisition in 2023 brought the technology into its portfolio. The results from the phase two trial of Nordisk’s treatment could help Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP)’s stock. Oppenheimer, for its part, is impressed with the firm’s cash reserves, as it outlines that Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) “is well funded, with the current cash balance supporting operations through key catalysts through 2026.”

Page 26 of 32